Navigation Links
ResMed Inc. Announces Record Financial Results For The Quarter Ended And Nine Months Ended March 31, 2013
Date:4/25/2013

SAN DIEGO, April 25, 2013 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended March 31, 2013.  Revenue for the quarter ended March 31, 2013 was $383.6 million, a 10% increase (also a 10% increase on a constant currency basis) over the quarter ended March 31, 2012.  For the quarter ended March 31, 2013, net income was $84.9 million, an increase of 31% compared to the quarter ended March 31, 2012.  Diluted earnings per share for the quarter ended March 31, 2013 were $0.58, an increase of 32% compared to the quarter ended March 31, 2012. 

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

SG&A expenses were $109.6 million for the quarter ended March 31, 2013, an increase of $7.7 million, or 8% (also an 8% increase on a constant currency basis) compared to the quarter ended March 31, 2012.  SG&A costs were 28.6% of revenue in the quarter ended March 31, 2013, compared to 29.2% for the quarter ended March 31, 2012.
 

R&D expenses were $31.2 million for the quarter ended March 31, 2013, an increase of $2.8 million, or 10% (an 11% increase on a constant currency basis) compared to the quarter ended March 31, 2012.  R&D expenses were 8.1% of revenue in the quarter ended March 31, 2013, consistent with 8.1% for the quarter ended March 31, 2012.

The company amortized acquired intangibles of $2.5 million ($1.9 million, net of tax) during the quarter ended March 31, 2013.  Stock-based compensation costs incurred during the quarter ended March 31, 2013 of $10.2 million ($7.2 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and our employee stock purchase pl
'/>"/>

SOURCE ResMed Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ResMed Noninvasive Ventilation Device Cleared by FDA for COPD Treatment
2. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
3. ResMed Takes Action to Enforce Patents
4. Buoyed by Forecasts, Where 2013 Leads - Research Report on ResMed Inc., Zimmer Holdings, Inc., Waters Corporation, Covidien PLC, and Medtronic, Inc.
5. ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2012
6. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
7. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2012
8. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
9. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
10. ResMed Launches Narval™ CC Mandibular Repositioning Device in the US
11. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014  GenSpera, Inc. (OTCQB: ... the treatment of cancer, announces that Kareg Corporation,s ... has issued the following research report on  the ... , Director of Research, Kareg Corporation, Initiating Coverage ... Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf ...
(Date:7/14/2014)... -- Medac Pharma, Inc., a privately held pharmaceutical company ... improving the effectiveness of existing medicines, announced that ... approved Rasuvo™, a subcutaneous injectable methotrexate (MTX) therapy ... polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. Rasuvo ... from 7.5 mg to 30 mg in 2.5 ...
(Date:7/14/2014)... Ill., July 14, 2014  Abbott (NYSE: ABT) announced today ... pharmaceuticals business to Mylan for equity ownership of a ... and Abbott,s developed markets pharmaceuticals ... represents a value of approximately $5.3 billion based on ... portion of this business generated approximately $2 billion in ...
Breaking Medicine Technology:Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 2Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 4Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 5Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 7Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 8Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 2Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 4Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 5Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 6Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 7
... Va., Aug. 26 Radiation in any form brings risk. ... designed with safeguards in mind to minimize the risk and ... if a patient presents with a breast lump that can ... professionals must employ the most appropriate diagnostic tools that identify ...
... Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company -- JERUSALEM, August 26, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, ...
Cached Medicine Technology:Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics 2Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics 3Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 2Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 3Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 4Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 5Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 6
(Date:7/14/2014)... The report “Biofertilizers Market ... Type (Cereals & Grains, Pulses & Oilseeds, ... Azospirillium, Cyanobacteria, Phosphate solubilizing bacteria), & by ... 2019” defines and segments the biofertilizers market ... values for the market. It also identifies ...
(Date:7/14/2014)... E.J. Mundell ... News) -- When an 11-year-old boy in San Diego ... the nickel in his family,s iPad. They also ... iPad,s metal surfaces with a form-fitting case. The ... personal effects as potential sources of nickel exposure" and ...
(Date:7/14/2014)... specialists look back on 40 years of the Glasgow Coma ... research and clinical practice, in a new Personal View published ... The Personal View is published on the 40th anniversary of ... Since this seminal publication, the Glasgow Coma Scale has ... conscious level, the clinical hallmark of acute brain injury. The ...
(Date:7/14/2014)... to ignore irrelevant stimuli underlies the impaired working memory ... reports a new study in the current issue of ... good at focusing on the information that we are ... thoughts that aren,t relevant. However, memory impairment in schizophrenia ... this filtering process, which Dr. Teal Eich at Columbia ...
(Date:7/14/2014)... N.J. (PRWEB) July 14, 2014 Documented ... Laurel, has announced the publication of its first military memoir ... crash on Black Thursday in October 1943 and 19 months ... to return home and build the American dream. , ... and the American dream (Amazon) is a true ...
Breaking Medicine News(10 mins):Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 2Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 3Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 4Health News:iPads Can Trigger Nickel Allergies in Kids 2Health News:'Noisy' memory in schizophrenia 2Health News:Mount Laurel-based Documented Legacy to Release Military Memoir of World War II Air Force Vet Who Survived Black Thursday Crash 2
... HealthDay Reporter , FRIDAY, March 16 (HealthDay ... for kids who have a genetic predisposition to aggressive ... new research suggests. "There,s an intricate interplay between ... assistant professor of criminology at the University of Texas ...
... Musicians and their instruments often make beautiful music together, but ... of musical instruments may put their owners at risk for ... Contact dermatitis is a rash caused by an irritant or ... components of musical instruments -- such as metals, exotic woods ...
... Obesity appears to significantly increase the risk of death ... mortality even among those prescribed 18 or fewer pills ... as a marker of increased vulnerability," said Robert Langer, ... and Prevention | Nutrition, Physical Activity and Metabolism 2012 ...
... companies in overcoming common issues associated with crystal formation ... The software, which has been developed at the University ... Centre (CCDC) is called Visual HABIT. It offers a ... companies to adopt a more ,bottom up, approach to ...
... , FRIDAY, March 16 (HealthDay News) -- People with ... risk for health problems that affect the heart, an ... of psoriasis. Chronic inflammation is also a characteristic of ... said Dr. Joel Gelfand, an assistant professor of dermatology ...
... facilitate efficient production of chemicals, materials and fuels from ... Excellence (CoE) in White Biotechnology Green Chemistry Research ... or cell factories, for producing new useful compounds from ... for example, for manufacturing bioplastics or in medical applications. ...
Cached Medicine News:Health News:With Spanking, Nature and Nurture Create More Aggression, Study Suggests 2Health News:With Spanking, Nature and Nurture Create More Aggression, Study Suggests 3Health News:Tooting Your Horn Can Raise Risk for Skin Condition 2Health News:Obesity raises death risk tied to sleeping pills 2Health News:Obesity raises death risk tied to sleeping pills 3Health News:New technology to aid crystallization prediction 2Health News:Psoriasis Patients May Face Higher Heart Risk 2Health News:Novel plastics and textiles from waste with the use of microbes 2
This double-up gel dryer system, 100-120 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
... GelAir™ drying system utilizes a hot air drying ... dried on a clear cellophane support for easy ... a smooth, flat assembly surface for the drying ... frames at once. This 115 V, 60 Hz ...
... is an electrophoresis gel vacuum dryer that removes ... these gels onto cellophane or filter paper for ... which heat gels from above. The drying surface ... unit includes power cord, porous gel support, transparent ...
... The PRO6000 power supply is ... power supply product offering. It ... and genomic electrophoresis. This product ... proteomic applications such as microAmp ...
Medicine Products: